ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting
ReCor Medical, Inc. (ReCor), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the endovascular Paradise Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension.
- ReCor Medical, Inc. (ReCor), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the endovascular Paradise Ultrasound Renal Denervation (uRDN) System as a treatment for hypertension.
- Conducted as an international, multicenter study, RADIANCE II is a US FDA IDE, randomized, sham-controlled pivotal trial of the Paradise uRDN System in the treatment of patients with uncontrolled hypertension.
- Patients were to remain off antihypertensive medications throughout the 2 months of follow-up unless specified BP criteria were exceeded.
- ReCor Medical, headquartered in Palo Alto, CA, a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension.